Avalo Therapeutics Inc
AVTX
查看详细走势图
14.190USD
+1.040+7.91%
收盘 02/06, 16:00（美东）报价延迟15分钟
252.97M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+7.91%
5天
-6.09%
1月
-10.78%
6月
+70.76%
今年开始到现在
-21.86%
1年
+73.26%
查看详细走势图
TradingKey Avalo Therapeutics Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Avalo Therapeutics Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名178/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价36.11。中期看，股价处于平稳状态。近一个月，市场表现非常差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Avalo Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看好
Avalo Therapeutics Inc亮点
亮点风险
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology. AVTX-009 is in the Phase II LOTUS trial for hidradenitis suppurativa (HS).
业绩增长期
公司处于发展阶段，最新年度总收入441.00K美元
估值低估
公司最新PE估值-1.06，处于3年历史低位
机构加仓
最新机构持股15.54M股，环比增加1.40%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值804.08K
分析师目标
根据
11
位分析师
买入
评级
36.111
目标均价
+174.61%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Avalo Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Avalo Therapeutics Inc简介
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology. AVTX-009 is in the Phase II LOTUS trial for hidradenitis suppurativa (HS).
公司代码AVTX
公司Avalo Therapeutics Inc
CEONeil (Garry A)
网址https://www.avalotx.com/
相关品种
